Share ownership Neurizon Therapeutics Limited

NUZ

AU0000357261

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 10:03:32 12/02/2026 am IST			5-day change	1st Jan Change
0.0980 ^AUD	-2.00%		+4.26%	+15.29%

20/01	Neurizon Therapeutics Obtains Global Trademark Protection in Major Markets	MT
20/01	Neurizon Therapeutics secures registered trademark protection for Neurizon® across all priority global markets	RE

Share class: Neurizon Therapeutics Limited

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	44,50,24,049	35,47,13,820 ( 79.71 %)	0	79.71 %

Major shareholders: Neurizon Therapeutics Limited

Name	Equities	%	Valuation
Loon Tan Chek 4.702 %	3,90,00,000	4.702 %	2 M $
Marcus Hughes 1.772 %	1,47,00,943	1.772 %	926 894 $
Sam Wright 0.6131 %	50,85,470	0.6131 %	320 639 $
Michael Thurn 0.3459 %	28,69,276	0.3459 %	180 908 $
Kathryn MacFarlane 0.0323 %	2,67,656	0.0323 %	16 876 $
Sergio Duchini 0.0323 %	2,67,656	0.0323 %	16 876 $

Breakdown by shareholder type

Individuals	7.5%
Unknown	92.5%

Based on 1000 largest holdings

Geographical origin of shareholders

Individuals

7.5%

Based on 1000 largest holdings

Neurizon Therapeutics Ltd, formerly PharmAust Limited, is an Australia-based clinical-stage biotechnology company. The Company is engaged in advancing treatments for neurodegenerative diseases. The Company is focused on developing its lead drug candidate, NUZ-001, for the treatment of Amyotrophic Lateral Sclerosis (ALS), which is the common form of motor neuron disease. ALS is a devastating neurodegenerative condition that primarily affects nerve cells that control voluntary muscles.

Employees

Sector

Pharmaceuticals

Calendar

26/02 - Q2 2026 Earnings Release (Projected)

More about the company